Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Appropriations Committee Embraces Clinical Trial Issues In FY 2022 US FDA Budget Bill

Executive Summary

Report language includes several mentions of improving trial diversity and recruitment, while bill offers a 5% increase in funding.

You may also be interested in...



FDA Draft Guidance Calls For Trial Diversity Plans

Many companies have been signaling their commitment to diversity and inclusion in trials, but the new draft guidance spells out how they should address it and what the FDA wants to see.

Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

Omnibus package also gives FDA expanded authority over nicotine products and creates President Biden’s Advanced Research Projects Agency for Health.

House Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

The bill also would give the FDA expanded authority over nicotine products and create President Biden’s Advanced Research Projects Agency for Health.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel